NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis $1.91 0.00 (0.00%) (As of 09/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aerovate Therapeutics alerts: Email Address About Aerovate Therapeutics Stock (NASDAQ:AVTE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aerovate Therapeutics alerts:Sign Up Key Stats Today's Range$1.88▼$1.9650-Day Range$1.64▼$2.0152-Week Range$1.25▼$32.42Volume226,567 shsAverage Volume513,610 shsMarket Capitalization$55.05 millionP/E RatioN/ADividend YieldN/APrice Target$2.25Consensus RatingHold Company OverviewAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More… My big AI project… (Ad)On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. Aerovate Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 28th PercentileAerovate Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 857th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingAerovate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAerovate Therapeutics has received no research coverage in the past 90 days.Read more about Aerovate Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.74) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aerovate Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.49% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aerovate Therapeutics has recently increased by 9.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.49% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aerovate Therapeutics has recently increased by 9.48%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.44 News SentimentAerovate Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aerovate Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for AVTE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.90% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Aerovate Therapeutics' insider trading history. Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTE Stock News HeadlinesAerovate Therapeutics to Explore Strategic AlternativesJuly 8, 2024 | globenewswire.comInvestigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLCJune 21, 2024 | globenewswire.comBill Gates’ Next Big Thing: “Exegesis AI”In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.September 17, 2024 | Brownstone Research (Ad)Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law FirmJune 20, 2024 | globenewswire.comSHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & LevitonJune 17, 2024 | globenewswire.comAerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionJune 17, 2024 | globenewswire.comAerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH MarketJune 11, 2024 | seekingalpha.comAnalysts Are Bullish on Top Healthcare Stocks: Aerovate Therapeutics (AVTE), Exact Sciences (EXAS)May 22, 2024 | markets.businessinsider.comSee More Headlines AVTE Stock Analysis - Frequently Asked Questions How have AVTE shares performed this year? Aerovate Therapeutics' stock was trading at $22.63 at the start of the year. Since then, AVTE shares have decreased by 91.6% and is now trading at $1.91. View the best growth stocks for 2024 here. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) issued its earnings results on Monday, August, 12th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.10. When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share. Who are Aerovate Therapeutics' major shareholders? Aerovate Therapeutics' top institutional shareholders include Atlas Venture Life Science Advisors LLC (6.24%), Deerfield Management Company L.P. Series C (4.90%), Affinity Asset Advisors LLC (0.69%) and SG Americas Securities LLC (0.62%). Insiders that own company stock include David S Grayzel, Hunter Gillies, George A Eldridge, Ralph Niven, Benjamin T Dake, Marinus Verwijs and Timothy P Noyes. View institutional ownership trends. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/12/2024Today9/17/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVTE CUSIPN/A CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$2.25 High Stock Price Target$3.00 Low Stock Price Target$2.00 Potential Upside/Downside+17.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-83.65% Return on Assets-72.26% Debt Debt-to-Equity RatioN/A Current Ratio6.51 Quick Ratio6.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book0.48Miscellaneous Outstanding Shares28,822,000Free Float21,645,000Market Cap$55.05 million OptionableOptionable Beta1.03 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AVTE) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredI’m giving you the name of this investment for freeNow that the Federal Reserve lowered interest rates, this investment could easily go up 50%.Porter & Company | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.